ストックスクリーナーアプリを入手
21.27
4.01%
0.82
アフターアワーズ：
21.35
0.08
+0.38%
Immunovant Inc (IMVT) 最新ニュース
Immunovant CEO Peter Salzmann sells $322,057 in stock to cover tax obligations - Investing.com Canada
Immunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now? - Insider Monkey
Immunovant’s chief medical officer Macias sells $42,867 in stock By Investing.com - Investing.com Nigeria
Immunovant's chief medical officer Macias sells $42,867 in stock - Investing.com India
Immunovant Executives Sell Shares to Cover Tax Obligations - TradingView
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently - MSN
Biotech Kingpin: Why Insiders Are Betting Big on Immunovant - Reporteros del Sur -
ABC Arbitrage SA Invests $734,000 in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Banque Pictet & Cie SA Sells 13,440 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
(IMVT) Investment Analysis and Advice - Stock Traders Daily
Immunovant Inc [IMVT] Shares Rise 3.33 % on Thursday - Knox Daily
Guggenheim cuts Immunovant stock target to $44, maintains Buy - MSN
Immunovant (NASDAQ:IMVT) Given New $44.00 Price Target at Guggenheim - MarketBeat
Immunovant's Key Batoclimab Trial Catalysts Expected By MarchCan The Stock Bounce Back? - RTTNews
Immunovant FY2025 EPS Estimate Raised by Leerink Partnrs - MarketBeat
Immunovant stock hits 52-week low at $19.08 amid challenges By Investing.com - Investing.com Canada
Immunovant stock hits 52-week low at $19.08 amid challenges - Investing.com
Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Nasdaq
Immunovant (NASDAQ:IMVT) Hits New 12-Month Low After Earnings Miss - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Shares Acquired by abrdn plc - MarketBeat
Guggenheim cuts Immunovant stock target to $44, maintains Buy By Investing.com - Investing.com Australia
IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus - MSN
Immunovant (NASDAQ:IMVT) Price Target Cut to $44.00 by Analysts at Guggenheim - Defense World
Immunovant (NASDAQ:IMVT) Reaches New 12-Month Low on Disappointing Earnings - Defense World
Immunovant’s (IMVT) Buy Rating Reiterated at HC Wainwright - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Receives $47.00 Consensus PT from Analysts - Defense World
Oppenheimer Adjusts Price Target on Immunovant to $54 From $53, Keeps Outperform Rating - Marketscreener.com
Immunovant (NASDAQ:IMVT) Issues Quarterly Earnings Results - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Immunovant (NASDAQ:IMVT) Shares Down 5% Following Weak Earnings - MarketBeat
HC Wainwright Reaffirms Buy Rating for Immunovant (NASDAQ:IMVT) - MarketBeat
Immunovant Inc [NASDAQ: IMVT] Sees Decrease in Stock Value - Knox Daily
IMVT’s Market Whiplash: -17.80% YTD Decline, -17.34% Plunge in 30 Days - The InvestChronicle
Immunovant (NASDAQ:IMVT) Stock Price Down 5% on Disappointing Earnings - Defense World
Immunovant Reports Progress Amid Increased R&D Costs - TipRanks
Immunovant (NASDAQ:IMVT) Sets New 1-Year LowHere's What Happened - MarketBeat
Immunovant's Fiscal Q3 Loss Widens -February 06, 2025 at 07:40 am EST - Marketscreener.com
Immunovant Inc. (IMVT) reports earnings - Quartz
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):